AI PRICE FORECAST
LLY Stock Forecast & AI Price Prediction
Eli Lilly and · Healthcare · Drug Manufacturers - General
LLY live signal snapshot
Shares of LLY were last at $1437.29, up 0.35% on the day, trading within 1.1% of its 52-week high of $1453.00. The model's verdict for LLY right now: BUY (71% confidence). The short-term averages are tangled, giving no clean trend signal either way. Its one-month projection is about $1483.53, a 3.2% move from the last price.
LLY's 14-day RSI is 76.6 — overbought territory, where short-term pullbacks or consolidation are common. The MACD indicator sits over its signal line, and the histogram reading of 5.48 shows buying pressure building. The 50-day moving average ($1230.06) sits 11.3% above the 200-day ($1105.21) — a "golden cross" structure that typically supports the longer-term uptrend.
29 Wall Street analysts covering LLY put the average price target at $1453.40 (range $940.00–$1690.00), implying 1.1% upside from the current price. The current recommendation trend leans bullish: 26 Buy/Strong Buy ratings vs 2 Sell/Strong Sell (and 3 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive LLY dashboard for numbers updated throughout today's session.
About Eli Lilly and
Eli Lilly and Company (LLY) is a drug manufacturers - general company in the healthcare sector, headquartered in Indianapolis, IN, United States. Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. It has a market value of about $1.28 trillion and roughly 50,000 full-time employees. With a beta of 0.39, the stock has historically moved less than the overall market.
LLY performance vs. the market
LLY is up 33.7% so far in 2026, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has gained 48.7%, 37.2 points better than the S&P 500. Its +23.2% move over the past month extends a +18.9% three-month run.
| Period | LLY | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +23.2% | +11.4% | −2.3% |
| 3 months | +18.9% | +12.2% | −2.3% |
| Year to date | +33.7% | +22.1% | +11.4% |
| 1 year | +48.7% | +28.3% | +11.5% |
Eli Lilly and financials at a glance
Eli Lilly and's most recent quarter (ended Sep 30, 2026) brought in $24.4 billion of revenue and net income of $6.5 billion (a 26.4% net margin). Revenue was up 38.6% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 46.7 on trailing earnings of $30.81 per share. Trailing free cash flow was $9.3 billion, and total debt equals 123% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $24.4B | $6.5B |
| Jun 30, 2026 | $23.0B | $7.1B |
| Mar 31, 2026 | $19.8B | $7.4B |
| Dec 31, 2025 | $19.3B | $6.6B |
LLY vs. its peers
LLY's +33.7% this year ranks ahead of 1 of the 5 big healthcare names below. The strongest of the group this year is Amgen (AMGN, +43.0%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
| Johnson & Johnson (JNJ) | $280.41 | +35.5% | 42.6 | BUY |
| AbbVie (ABBV) | $294.98 | +29.1% | 50.7 | BUY |
| Merck & Co. (MRK) | $147.18 | +39.8% | 148.7 | HOLD |
| Amgen (AMGN) | $468.11 | +43.0% | 27.1 | BUY |
| Gilead Sciences (GILD) | $169.73 | +38.3% | — | BUY |
LLY stock: common questions
What is the LLY stock price target?
29 Wall Street analysts put the average 12-month target at $1453.40, in a range of $940.00–$1690.00, versus a recent price of $1437.29. Stock Pulse 247's model projects about $1483.53 over the next month.
Is LLY a buy right now?
Our AI model currently rates LLY a BUY at 71% confidence. Among analysts, 26 rate it Buy or Strong Buy, 3 Hold and 2 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has LLY stock performed this year?
LLY is up 33.7% so far in 2026, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has gained 48.7%, 37.2 points better than the S&P 500. Its +23.2% move over the past month extends a +18.9% three-month run.
What is LLY's 52-week high and low?
LLY has traded between $850.51 and $1453.00 over the past 52 weeks; at $1437.29 it is within 1.1% of its 52-week high of $1453.00.
What sector is LLY in, and who are its peers?
LLY is in the healthcare sector (drug manufacturers - general). Its largest peers on Stock Pulse 247 include Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co. (MRK), Amgen (AMGN).
How accurate is the LLY forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines LLY's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.